Sonidegib
- Generic Name
- Sonidegib
- Brand Names
- Odomzo
- Drug Type
- Small Molecule
- Chemical Formula
- C26H26F3N3O3
- CAS Number
- 956697-53-3
- Unique Ingredient Identifier
- 0RLU3VTK5M
- Background
Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
- Indication
用于治疗那些在手术后或放射治疗后出现病情复发，或是不适合采用手术或放射治疗的局部晚期基底细胞癌（BCC）患者。BCC是常见皮肤癌，占所有非黑色素瘤病例的80%。
- Associated Conditions
- Refractory, locally advanced Basal cell carcinoma
Sun Pharma to Acquire Checkpoint Therapeutics in $355 Million Deal for Novel Skin Cancer Treatment
• Sun Pharmaceutical Industries will acquire Checkpoint Therapeutics for $355 million upfront, with stockholders receiving $4.10 per share plus a contingent value right worth up to $0.70 per share based on European approval milestones.
• The acquisition adds UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma (cSCC), to Sun Pharma's global onco-dermatology portfolio.
• Sun Pharma plans to leverage its global presence to accelerate patient access to UNLOXCYT in the United States, Europe, and other markets worldwide, addressing a significant unmet need in the second most common skin cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath